Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71843 | 0.94 | GLP1R (0.51) | GLP1RFOLH1SELPRIMKLANAALAD2 | |
| SCHEMBL71109 | 0.89 | GLP1R (0.57) | GLP1RFOLH1NOD1SELPRIMKLA | |
| SCHEMBL71091 | 0.89 | GLP1R (0.57) | GLP1RFOLH1NOD1SELPRIMKLA | |
| SCHEMBL72060 | 0.89 | GLP1R (0.57) | GLP1RFOLH1NOD1SELPRIMKLA | |
| SCHEMBL15073596 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL12673880 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL12674091 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL8247968 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL13294071 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 | |
| SCHEMBL12674092 | 0.88 | GLP1R (0.61) | GLP1RFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | GLP1R 1/4885FOLH1 274/4885NOD1 933/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885FOLH1 450/4885NOD1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.